Vaxart Stock Is Surging As Its Oral COVID-19 Vaccine Can Potentially Trigger Immunity Against Variants

Vaxart Inc VXRT has announced new data from the Phase 1 trial evaluating its oral COVID-19 vaccine candidate, dubbed as VXA-CoV2-1.
Data obtained showed substantial CD8+ T-cell responses against SARS-Cov-2 and showed cross-reactivity against diverse endemic coronaviruses such as 229E, NL63, HKU1, and OC43.
In a comparative experiment, Phase 1 study data was compared to T-cell responses from volunteers subsequently vaccinated with the Moderna Inc’s MRNA or Pfizer Inc PFE - BioNTech SE BNTX vaccines, indicating the mRNA vaccines induced fewer T-cell responses.
“The strength of T-cell responses against both S and N proteins, which we targeted, leads us to believe that VXA-CoV2-1 offers a promising solution to variants,” said Dr. Sean Tucker, chief scientific officer at Vaxart.
Price Action: VXRT shares up 17.5% at $9.42 in the premarket session on the last check Tuesday.